摘要
INTRODUCTION Cancer pain remains a multifaceted clinical challenge. Despite advancements in pharmacological and interventional pain management, cancer pain remains under-recognized and undertreated, leading to poor functional status, quality of life, and increased morbidity. Effective pain management requires the identification of underlying pain mechanisms. Applying the concept of precision pain medicine for cancer pain management is by classifying pain mechanisms into three major pain phenotypes, as defined by the International Association for the Study of Pain (IASP), i.e., nociceptive, neuropathic, and nociplastic pain. Pain phenotyping offers a framework to plan pain management strategies based on distinct biological, sensory, and psychological profiles, which can revolutionize cancer pain management. Integrating this personalized approach with treatment strategies takes steps beyond the traditional concept of the “one-size-fits-all” model. This article explores the concept of pain phenotyping and its role in enhancing personalized cancer pain treatment.[1,2] CANCER PAIN PHENOTYPING During surgery, chemotherapy, and radiotherapy, most of the cancer pain is nociceptive and/or neuropathic type. Nociceptive pain, caused by tissue inflammation and damage, is often presented with painful movement. Neuropathic pain is commonly encountered in postcancer treatment or cancer survivors. Patients present with sensory and motor symptoms, including numbness, tingling, weakness, and burning pain. Neuropathic pain is triggered by nerve damage due to localized nerve compression/invasion, peripheral nerve damage during the cancer surgery (e.g. the intercostobrachial nerve during axillary lymph node dissection), chemotherapy induced and radiation induced. Cancer patients on taxane or platinum-based chemotherapy are most likely to experience chemotherapy-induced peripheral neuropathy.[3,4] The third mechanism for pain, in addition to nociceptive and neuropathic pain, is “nociplastic” pain, which was introduced in 2017. Previously, the term “central sensitisation” was broadly used for any persistent, widespread chronic pain. The IASP defines nociplastic pain as “pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain.” Whereas the pain mechanisms underlying nociceptive and neuropathic pain are apparent, the underlying mechanisms for nociplastic pain are not entirely understood; central sensitization and altered pain modulation, i.e., decreased inhibition and increased facilitation, play essential roles. Many recent studies suggest that nociplastic pain is present in a subgroup of cancer patients. The patient with nociplastic pain complains of widespread multifocal pain, fatigue, poor sleep, depressed mood, and sensitivity to sensory stimuli. The diagnosis of nociplastic pain is often delayed due to nonspecific symptoms. The 2021 IASP released clinical criteria and grading system for musculoskeletal system-related nociplastic pain, which facilitates early identification of patients according to pain phenotype. These criteria have replaced the IASP 2014 clinical criteria for predominant central sensitization pain.[2,5] The concept of nociplastic pain applies not only to chronic noncancer pain but also to patients with cancer. Recently, Cancer Pain Phenotyping (CANPPHE) Network, an international and interdisciplinary group, applied IASP 2021 clinical criteria for nociplastic pain for cancer pain. It is a seven-step clinical decision-making tree to diagnose postcancer nociplastic pain, including (1) postcancer pain >3 months, (2) regional distribution, (3) entirely nociceptive pain, (4) entirely neuropathic pain, (5) evoked pain sensitivity phenomenon (e.g., static or dynamic mechanical allodynia, heat or cold allodynia), (6) history of pain sensitivity, and (7) at least one comorbid condition. It guides pain physicians/oncologists in identifying the pain phenotype in cancer patients and tailoring pain management accordingly, which is seemingly a step toward precision pain medicine for cancer patients.[6] Pain phenotyping in cancer patients is essential due to various reasons. Neuropathic and mixed cancer pain are more challenging to treat than pure nociceptive pain. The selection of pain management needs to consider the pain phenotype as mechanism-based pain management, which has better outcomes than symptomatic or diagnosis-based management.[7,8] However, the management of nociplastic pain is challenging, as pain complaints are often vague and associated with subjective symptoms. Specific clinical findings are absent. Thus, nociplastic pain management is frustrating for both pain physicians and patients. Patients with nociplastic components are at higher risk for opioid-induced hyperalgesia. Individualized approaches for multimodal therapies, including psychotherapies, psychotropic drugs (such as antidepressants and gabapentinoids), and physical exercise should be considered.[9,10] Classifying cancer pain to one phenotype group is an oversimplification, as mixed-pain symptoms with a substantial overlap of the mechanism are not uncommon. Most of the time, cancer pain is managed on a “trial and error” basis or “concept of exclusion,” which is influenced by the pain physician’s perception. Although our understanding of cancer pain and associated molecular mechanisms has increased over the last many years, applying these concepts in the real world remains a dilemma. CONCLUSION Cancer patients suffer pain due to multiple contributing factors. Pain physician needs to look beyond the typical nociceptive and neuropathic pain, resulting in poor response in many cancer patients. Appropriate categorization of pain as nociceptive, neuropathic, nociplastic, or mixed can ensure targeted pain management. The evaluation of spiritual and psychosocial components might clarify additional areas for precise care.